Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | OXTR | P30559 | 1/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | CLK1 | P49759 | 1/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5888740 | 0.90 | GFER (0.40) | PPARGMAPK14FFAR1EGLN1GFER | |
| SCHEMBL5885741 | 0.87 | PPARG (0.37) | PPARGMAPK14FFAR1EGLN1GFER | |
| SCHEMBL5886056 | 0.86 | MAPK14 (0.38) | PPARGMAPK14FFAR1GFERHCRTR1 | |
| SCHEMBL5885789 | 0.85 | PPARG (0.39) | PPARGMAPK14FFAR1EGLN1GFER | |
| SCHEMBL5885757 | 0.84 | PLAU (0.35) | PPARGMAPK14EGLN1 | |
| Hydrochloric Acid SCHEMBL5885795 | 0.83 | PLAU (0.35) | PPARGMAPK14EGLN1 | |
| SCHEMBL5885273 | 0.83 | PPARG (0.40) | PPARGMAPK14FFAR1EGLN1GFER | |
| SCHEMBL5885868 | 0.81 | PPARG (0.36) | PPARGMAPK14FFAR1EGLN1GFER | |
| SCHEMBL5888737 | 0.80 | GFER (0.46) | PPARGFFAR1EGLN1GFERKCNN4 | |
| SCHEMBL5885785 | 0.80 | KMT2A (0.39) | PPARGFFAR1EGLN1GFERKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7005437-B2 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2006-02-28 | — | — | US | disclosed |
| EP-1404648-A1 | AMIDINE SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES WITH AN ANTITHROMBOTIC AND FACTOR XA INHIBITING ACTION | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003101942-A1 | AMIDINE SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES WITH AN ANTITHROMBOTIC AND FACTOR XA INHIBITING ACTION | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-11 | — | — | WO | disclosed |
| US-20030045712-A1 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045712-A1 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | F2, F12, F3 | PPARG 2510/4885MAPK14 4663/4885FFAR1 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.